Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: wolfdog2 who wrote (1136)	8/10/1998 8:51:00 PM
From: ROBERT M. SILVER	Respond to of 1491

A difference of opinion from Arnie I am a firm advocate of freedom of speech on this thread and I have engaged in a spirited exchange with the princess emeritus of this thread when she took me on for criticizing management over the Castle Creek debacle. I was accused of promoting a proxy fight, preparing to launch a shareholders class action and a few other misdemeanors and high crimes. So in that light, I respect your right Arnie to make the statements you made but some are not vested with reality, I have to respond The existence of a large number of shorts is potentially a very bullish or constructive for the price of the stock. For when the stock goes up and the shorts start covering, it drives the rally even further. I love to see a large short position because I know eventually they have to buy the stock they have shorted. 2) I am against the dilution of our shares of stock. But the mere fact that management has received authorization to increase the shares to 60 million does not mean ipso facto that they are going to do mischief and somehow cheat the sharehlders. The stock could be used to acquire funds to handle phase 3 trials of Hu-211, or to acquire other companies, or to buy technology, or product, or a variety of things. 3) Most of the warrants that have been issued (other than to CC) have been given to officers and key employees of the company. I do not think these people will exercise the warrants and then sell the stock, rather I believe they will hold the stock if they exercise and keep it in strong hands. 4) I think that all current estimates for both the sales of Lotemax and Alrex, as well as estimates of the future stock price are on the low side. Both the number os Bob Sturza, and Neuroinvester, will be exceeded IMHO. In short, I am looking for double figures when a partner is announced for phase 3 and Pharmos goes forward. Regards, Robert

To: wolfdog2 who wrote (1136)	8/10/1998 8:54:00 PM
From: David Israel-Rosen	Read Replies (5) \| Respond to of 1491

Hello Everyone: I would like to comment about the issue of lack of Corporate Strategy of Pharmos. If I understand it correctly PARS strategy is as follows: 1) leverage DISCOVERY, Research and Development Expertise in Israel while leaving the followings to others: Sales and Marketing large scale clinical Trials 2) The company focuses (because of strategic or accidental reasons) on three areas of Drug Research and Development: Eyecare (2 approved Rx with 3rd forthcoming) Trauma, stroke etc (HU211) Cancer 3) The strategy is to leverage the 40+ PARS employees and deliver as much as possible output out of these 3 areas. 4) The CURRENT test is tactical. It requires execution and MUCH luck but not much else... 5) If HU211 is as big as we Hope it is, we are looking at a Billion $ Valuation real soon. If it is not...I do not know 6) Market price always catches up with Reality. The strategy is in place all is left is to execute and... 7) Pray. Nice to be back. Good luck to all David